Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tumor Growth Factors in Hepatocellular Carcinoma

This study has been completed.
Information provided by (Responsible Party):
Jung-Fa,Tsai, Kaohsiung Medical University Chung-Ho Memorial Hospital Identifier:
First received: February 26, 2008
Last updated: April 17, 2013
Last verified: April 2013

Malignant cells frequently produce many tumor growth factors to autocidal or endocrinal proliferate growth, metastasis,or angiogenesis about tumor cells. By studying tumor growth factors in hepatocellular carcinoma, one may know the tumor behavior, its relationship with clinical manifestation or invasion, and could be used as diagnostic or prognostic tools.This study aims to study the relationship between tumor growth factors in HCC ant its clinical relevance.

Condition Intervention
Hepatocellular Carcinoma
Biological: tumor growth factor concentration

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Insulin-like Growth Factors (IGF) Axis (IGFs, Its Binding Proteins,Receptors), Transforming Growth Factor Alpha and Beta 1 and Epidermal Growth Factor in the Urine and Serum of Patients With Hepatocellular Carcinoma.

Resource links provided by NLM:

Further study details as provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:

Primary Outcome Measures:
  • mortality [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • distant metastasis [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Blood and/or urine

Enrollment: 400
Study Start Date: January 2007
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Specific tumor growth factors (IGFs, its binding proteins,receptors; transforming growth factor alpha and beta 1 and epidermal growth factor) in the urine and serum will be measured in patients with hepatocellular carcinoma and healthy controls
Patients with hepatocellular carcinoma and Healthy controls
Biological: tumor growth factor concentration
spot urine or blood collection will be used to measure specific tumor growth factor
Other Names:
  • urine concentration of tumor growth factor
  • serum concentration of tumor growth factor

Detailed Description:

The clinical relevance of patients will be evaluated by the concentrations of tumor growth factors.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients with aspiration cytology or biopsy proved HCC and sex- and age-matched healthy controls.


Inclusion Criteria:

  • Histology proven HCC

Exclusion Criteria:

  • No definitely diagnosed tumor
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00764140

Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan, 807
Sponsors and Collaborators
Kaohsiung Medical University Chung-Ho Memorial Hospital
Principal Investigator: Jung-Fa Tsai, M.D., Ph.D. Professor of Medine, Kaohsiung Medical University
  More Information

No publications provided

Responsible Party: Jung-Fa,Tsai, Professor of Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital Identifier: NCT00764140     History of Changes
Other Study ID Numbers: KMUH-IRB-960010
Study First Received: February 26, 2008
Last Updated: April 17, 2013
Health Authority: Taiwan: Department of Health

Keywords provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:
tumor growth factor

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions processed this record on November 23, 2014